Understanding how Pseudomonas aeruginosa can inhibit Mycobacterium abscessus infections
Official title: Surface dependent inhibition of Mycobacterium abscessus by Pseudomonas aeruginosa
Funded at Ohio State University · NIH-11092869 · Data updated 2026-11-12
This study looks at how two tough bacteria, Pseudomonas aeruginosa and Mycobacterium abscessus, interact with each other in people with cystic fibrosis, hoping to find new ways to fight off hard-to-treat infections.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | May 21, 2024 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $190,969 |
| NIH project number | 5R21AI181224-02 |
| Project ID | NIH-11092869 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with cystic fibrosis or other conditions that predispose them to infections caused by these bacteria.
✕Less likely to help
Patients who do not have infections caused by Pseudomonas aeruginosa or Mycobacterium abscessus may not benefit from this research.
What this research studies
This research investigates the interactions between two bacteria, Pseudomonas aeruginosa and Mycobacterium abscessus, which can cause difficult-to-treat infections, particularly in patients with cystic fibrosis. The study focuses on how P. aeruginosa can inhibit the growth of M. abscessus when both bacteria are present in biofilms, a common form of bacterial growth that makes infections harder to treat. By exploring these interactions, the research aims to uncover new strategies for combating antibiotic-resistant infections.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients suffering from antibiotic-resistant infections.
How similar studies have gone: Previous research has shown promising results in understanding bacterial interactions, but this specific approach is relatively novel.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Wozniak, Daniel J — Ohio State University
- Study coordinator: Wozniak, Daniel J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.